Related references
Note: Only part of the references are listed.A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
Robyn Scherber et al.
BLOOD (2011)
Evaluating the Serial Use of the Myelofibrosis Symptom Assessment Form for Measuring Symptomatic Improvement Performance in 87 Myelofibrosis Patients on a JAK1 and JAK2 Inhibitor (INCB018424) Clinical Trial
Ruben A. Mesa et al.
CANCER (2011)
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
A. Tefferi
LEUKEMIA (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
Ruben A. Mesa et al.
LEUKEMIA RESEARCH (2009)
JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies
William Vainchenker et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
Standardizing patient-reported outcomes assessment in cancer clinical trials: A patient-reported outcomes measurement information system initiative
Sofia F. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) - An international internet-based survey of 1179 MPD patients
Ruben A. Mesa et al.
CANCER (2007)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening
D Cella et al.
QUALITY OF LIFE RESEARCH (2002)
Medical progress: Myelofibrosis with myeloid metaplasia.
A Tefferi
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
